Can I read An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer on EtoBox?

An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer by Carlotta Antoniotti; Alessandra Boccaccino; Robert Seitz; Mirella Giordano; Aurélie Catteau; Daniele Rossini; Filippo Pietrantonio; Lisa Salvatore; Kimberly McGregor; Francesca Bergamo; Veronica Conca; Simone Leonetti; Federica Morano; Giorgio Papiani; Emiliano Tamburini; Maria Bensi; Sabina Murgioni; Douglas Teller Ross; Alessandro Passardi; Isabelle Boquet; Tyler J. Nielsen; Jérôme Galon; Matthew Gordon Varga; Brock L. Schweitzer; Chiara Cremolini is a Medicine article available to read on EtoBox.

What is An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer about?

Abstract Background: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5fluoruracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of metastatic colorectal cancer (mCRC) patients, with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune-checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. Methods: mCRC patients unselected for MMR status were randomized(1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). RT-qPCR by DetermaIO was performed on RNA purified from pre-treatment tumours of 132(61%) out of 218 enrolled patients. A binary result (IOpos versus IOneg) adopting the pre-established DetermaIO cut-point (0.09) was obtained, and an exploratory optimized cut-point (IOOPT) was computed in the overall population and in pMMR subgroup (IOOPTpos versus IOOPTneg). Results: DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumours were

Who reads An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer?

Author

Carlotta Antoniotti; Alessandra Boccaccino; Robert Seitz; Mirella Giordano; Aurélie Catteau; Daniele Rossini; Filippo Pietrantonio; Lisa Salvatore; Kimberly McGregor; Francesca Bergamo; Veronica Conca; Simone Leonetti; Federica Morano; Giorgio Papiani; Emiliano Tamburini; Maria Bensi; Sabina Murgioni; Douglas Teller Ross; Alessandro Passardi; Isabelle Boquet; Tyler J. Nielsen; Jérôme Galon; Matthew Gordon Varga; Brock L. Schweitzer; Chiara Cremolini

Publisher

American Association for Cancer Research (AACR)

Published

2023

Language

EN

Field

Medicine (Health Sciences)